Lung cancer (non-small cell)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Who can joinAdults
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
18 hospitals in India taking patients for this trial.
Hemato Oncology ClinicAhmedabadDirections ↗
KLES Dr. Prabhakar Kore Hospital & M.R.CBelagaviDirections ↗
SRV HospitalsBengaluruDirections ↗
All India Institute of Medical SciencesBhubaneswarDirections ↗
Ashwin HospitalCoimbatoreDirections ↗
Nizam's Institute of Medical SciencesHyderabadDirections ↗
Krishna Institute of Medical Sciences - KaradKaradDirections ↗
Kolhapur Cancer Centre Private LimitedKolhāpurDirections ↗
HCG Manavata Cancer CentreNashikDirections ↗
Advanced Centre for Treatment Research and Education in CancerNavi MumbaiDirections ↗
Jawaharlal Institute Of Postgraduate Medical Education And ResearchPuducherryDirections ↗
Grant Medical Foundation - Ruby Hall ClinicPuneDirections ↗
Sahyadri Super Speciality HospitalPuneDirections ↗
Lifepoint Multispeciality HospitalPuneDirections ↗
Regional Cancer Centre - ThiruvananthapuramThiruvananthapuramDirections ↗
Pacific Medical College & HospitalUdaipurDirections ↗
Tata Memorial Centre - Homi Bhabha Cancer HospitalVaranasiDirections ↗
Mahatma Gandhi Cancer Hospital and Research InstituteVisakhapatnamDirections ↗
Registry summary (technical)
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Sponsor: Eli Lilly and Company
NCT06119581 on ClinicalTrials.gov
Last updated on the registry 7 Oct 2026 · read by us 20 Oct 2026